Swedish Orphan Biovitrum AB (Sobi) was last night presented with a EURORDIS Award for its commercial and development portfolio in the field of rare diseases.
Swedish Orphan Biovitrum AB (Sobi) was last night presented with a EURORDIS Award for its commercial and development portfolio in the field of rare diseases. The award also recognized the company’s track record on access to drugs and its collaboration with patient organizations.
EURORDIS is Europe’s largest patient organization in rare diseases. Its CEO, Yann Le Camm, commented: “We are honored to acknowledge the commitment and achievements of the recipients of the EURORDIS Awards on the occasion of Rare Disease Day 2014.” This year, he added, Rare Disease Day puts the spotlight on care.
Sobi’s CEO, Geoffrey McDonough, said: “We are inspired to pioneer a world in which rare disease patients are diagnosed at birth,receive effective and sustainable therapy, and go on to live full and healthy lives.”
Other winners at the EURORDIS AWards included Orphan Europe, part of the Recordati group, which has nearly 25 years’ experience in bringing orphan drugs to market for rare diseases with seven products to date.